Table 1.
Demographic, clinical, and laboratory data of the methotrexate study cohort
| Characteristics of cohort | Value |
|---|---|
| Number of patients | 13 |
| Median age (range), years | 56 (32-78) |
| Number of males/females | 4/9 |
| Median interval from diagnosis (range), days | 7 (1-25) |
| Median duration of symptoms (range), months | 6.5 (2-12) |
| ACPA-positive patients, number (percentage) | 6 (46) |
| Rheumatoid factor-positive patients, number (percentage) | 9 (69) |
| Number of patients taking oral corticosteroids | 2 |
| Number of patients taking NSAIDs | 10 |
| Median duration between biopsies (range), days | 58 (45-70) |
| Number of patients presenting erosions (percentage) | |
| At baseline | 2 (15) |
| After 1 year | 7 (53) |
| Mean DAS28 (minimum, maximum) | |
| At baseline | 5.7 (3.9, 6.7) |
| After 3 months | 3.8 (1.8, 5.8) |
ACPA, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; NSAID, non-steroidal anti-inflammatory drug.